Biotechnology
+243
Cancer Treatment (2025 Update)
Novel cancer therapies dominate, spanning ADCs, cell therapies, and microbiome modulation to boost immune response. A focus on solid tumors and overcoming treatment resistance is clear.
👋🏼 Hey there! Bounce Watch here — I'm gathering key information from Cancer Treatment list.
Real-Time Scouting Assistant
1 startups received investments in the last 30 days.
Latest Investments
There are 6 highlights worth noting for this list.
Open Positions
2
Mentioned on News
3
Recently Funded
1
Latest Highlights
Explore Cancer Treatment featuring 250 Companies in Biotechnology Industry
|
|
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
S*Bio | - | Pioneering the future of cancer treatment through innovative small molecule drug... | S*BIO Pte, Ltd., a Singapore-based biotech company, specializes in discovering a... | - | - | - | - | 2000 | Biotechnology, Pharmaceutical | [email protected] |
1
Low
|
946
|
879 | 14 years ago | Private Equity | 3 | 143.5M | 38892 | 5 Kg1 pse | |
|
|
|
Optieum Biotechnologies I... | - | Revolutionizing Immunity – Optimizing CAR-T for Breakthrough Therapies | We are driving the evolution of next-generation CAR-T cell therapy with precisio... | - |
Japan
|
- | Japan (HQ) + 1 | 2020 | Biotechnology | - |
1
Low
|
11
|
1.1K (20%) | 3 years ago | Seed | 1 | 290.0M | 386 | 4 months ago | |
|
|
|
Intezyne Technologies | - | - | Intezyne is a clinical-stage biotechnology company focused on increasing the eff... | - |
United States
|
Tampa | United States (HQ) | 2004 | Biotechnology, Health Care | [email protected] |
1
Low
|
4
|
749 | 7 years ago | Series A | 2 | 10.5M | 444 | 7 years ago | |
|
|
|
SOLID Therapeutics | - | An early-stage oncology company aiming to treat solid tumors | SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the Un... | - |
Denmark
|
- | Denmark (HQ) | 2022 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
9
|
879 | 1 year ago | Convertible Note | 1 | Unknown | 18925 | 6 months ago | |
|
|
|
ImmTune Therapies | - | Simplifying cell therapy for accessible, affordable patient care. | ImmTune Therapies operates a cell therapy process designed to simplify complex b... | - | - | - | - | 2019 | Biotechnology, Health Care +3 | - |
1
Low
|
993
|
705 | 3 years ago | Seed | 2 | Unknown | 1168 | 2 years ago | |
|
|
|
ACM Biolabs | - | - |
ACM Biolabs • Innovative medicines through next generation targeted delivery. •... |
- |
Singapore
|
- | Singapore (HQ) + 2 | 2013 | Biotechnology, Health Care | [email protected] |
1
Low
|
19
|
287 (-100%) | 2 years ago | Series Unknown | 3 | 6.8M | 1441 | 5 months ago | |
|
|
|
CyGenica | - | Enabling SAFE, targeted and affordable intracellular delivery of therapeutics fo... |
What We Do CyGenica uses a non-viral, non-toxic platform to develop in vitro an... |
- |
Ireland
|
- | Ireland (HQ) + 1 | 2017 | Biotechnology | [email protected] |
1
Low
|
8
|
352 (-56%) | 3 years ago | Seed | 1 | 1.4M | 2808 | 4 months ago | |
|
|
|
Clarity Pharmaceuticals | - | Clarity is developing next-generation products to address the growing need for r... | Clarity is a clinical stage radiopharmaceutical company developing next-generati... | - |
Australia
|
- | Australia (HQ) | 2010 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
61
|
8.3K (73%) | 7 years ago | Series Unknown | 6 | 9.7M | 10691 | 4 months ago | |
|
|
-Biotech,-LLC.-logo.jpg "Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC."){kind=logo}
|
Hangzhou ImmuQuad(艾沐蒽)... | - | 杭州艾沐蒽生物科技有限公司 | Hangzhou ImmuQuad Biotech focuses on immune system and cancers. We provide human... | - |
China
|
Hangzhou | China (HQ) | 2016 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
1
|
1.2K (-14%) | 4 years ago | Series A | 2 | Unknown | 26 | 2 cx2 szb | |
|
|
|
Galera Therapeutics, Inc. | - | Transforming the science and treatment of cancer | Galera Therapeutics is focused on developing and commercializing a pipeline of n... | - |
United States
|
Malvern | United States (HQ) + 1 | 2009 | Biotechnology, Health and Wellness +1 | - |
1
Low
|
15
|
1.9K (-30%) | 2 years ago | Post Ipo Equity | 12 | 178.6M | 9408 | 1 year ago | |
|
|
|
IMVAQ Therapeutics | - | - | Imvaq is an innovative biotechnology company developing novel immuno-oncologics... | - |
United States
|
New York | United States (HQ) | 2018 | Biotechnology | - |
1
Low
|
2
|
288 | 4 years ago | Series B | 1 | 20.0M | 8796 | 1 2ow NTU | |
|
|
|
Curamir Therapeutics, Inc... | - | Finding RNA-targeted cures for cancer. | Curamir strives to improve patients' lives by developing transformative RNA-targ... | - |
United States
|
Woburn | United States (HQ) | 2019 | Biotechnology, Health and Wellness | - |
1
Low
|
1
|
754 (-100%) | 5 years ago | Series A | 1 | 10.0M | 101 | 2 58F brI | |
|
|
|
Proteolix | - | - | Not sure what to write? Check out your company's website.Proteolix, Inc. is a bi... | - |
United States
|
- | United States (HQ) | 2003 | Biopharma, Biotechnology +2 | [email protected] |
1
Low
|
12
|
972 | 16 years ago | Series C | 3 | 142.3M | 284 | 4 zJb 5Up | |
|
|
|
Cellectar Biosciences, In... | - | Learn more about pediatric and AYA clinical trial for HGG at www.pediatrichggtri... | Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused... | - |
United States
|
- | United States (HQ) | 2002 | Biotechnology, Health and Wellness +1 | [email protected] |
1
Low
|
37
|
2.2K (-63%) | 1 year ago | Post Ipo Equity | 12 | 148.5M | 3619 | 5 months ago | |
|
|
|
PIN Pharma | - | A pioneering biopharmaceutical firm dedicated to creating broad-based immuno-mod... | PIN Pharma is a private, venture-backed research and development company special... | - | - | - | - | 2011 | Biotechnology, Pharmaceutical | [email protected] |
1
Low
|
225
|
62 | 11 years ago | Series A | 1 | 6.8M | 31092 | 9 Wt3 cob | |
|
|
|
Adaptimmune | - | Designing and delivering cell therapies to transform the lives of people with ca... |
Adaptimmune is a fully integrated cell therapy company, designed and built from... |
- |
United Kingdom
|
Abingdon | United Kingdom (HQ) + 2 | 2008 | Biopharma, Biotechnology +1 | [email protected] |
1
Low
|
535
|
28.5K (154%) | 1 year ago | Post Ipo Debt | 9 | 499.5M | 50708 | 9 months ago | |
|
|
|
Nuvation Bio | - | Nuvation Bio is focused on treating the most difficult-to-treat cancers, for whi... | Nuvation Bio is a global biopharmaceutical company tackling some of the greatest... | - |
United States
|
New York | United States (HQ) + 2 | 2018 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
144
|
231 (-100%) | 4 years ago | Post Ipo Equity | 2 | 777.0M | 7544 | 4 months ago | |
|
|
|
Cytocares | - | Pioneering innovative medication development in the field of tumor immunity. | Cytocares offers innovative drug design for antibody novel medication creation a... | - | - | - | - | 2015 | Biotechnology | - |
1
Low
|
769
|
876 (-100%) | 2 years ago | Series A | 1 | 100.0M | 69596 | 5 bCq anN | |
|
|
|
Y-mAbs Therapeutics, Inc. | - | Innovative pediatric immunotherapies for Real-life Possibilities | Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the d... | - |
United States
|
New York | United States (HQ) + 1 | 2015 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
119
|
2.4K (-17%) | 4 years ago | Post Ipo Equity | 4 | 338.8M | 7887 | 4 months ago | |
|
|
|
TESARO, Inc. | - | - | TESARO is an oncology-focused business within GlaxoSmithKline (GSK) with a clear... | - |
United States
|
Waltham | United States (HQ) + 6 | 2010 | Biopharma, Biotechnology +1 | [email protected] |
1
Low
|
62
|
565 | 8 years ago | Post Ipo Equity | 8 | 1.1B | 31438 | 4 thd RHa | |
|
|
|
OncoSynergy | - | Physician-founded, patient-focused. |
Our vision: "Cancer treatment in one dose." OncoSynergy is a patient-focused... |
- |
United States
|
Stamford | United States (HQ) | 2011 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
5
|
207 (-100%) | 4 years ago | Series Unknown | 2 | 23.3M | 1265 | 8 Kt5 3f9 | |
|
|
|
Qihan Biotechnology Co.,... | - | A world in which cell and organ therapies are universally available to patients. | Qihan Biotech is a biotechnology company applying genome-editing technology to d... | - |
China
|
Hangzhou | China (HQ) | 2017 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
11
|
3.1K | 1 year ago | Series B | 4 | 116.3M | 25354 | 8 kFI 8at | |
|
|
|
Bellicum Pharmaceuticals,... | - | Bellicum is a clinical-stage biopharmaceutical company that is driving the futur... | Bellicum Pharmaceuticals, located near the Houston Medical Center, is engineerin... | - |
United States
|
Houston | United States (HQ) | 2003 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
23
|
885 (-37%) | 3 years ago | Post Ipo Equity | 15 | 324.6M | 9465 | 7 BGk fuV | |
|
|
|
Cidara Therapeutics | - | Leading the Science of Protection | Cidara Therapeutics is a biotechnology company using its proprietary Cloudbreak®... | - |
United States
|
San Diego | United States (HQ) | 2013 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
68
|
4.7K | 1 year ago | Post Ipo Equity | 9 | 413.4M | 6451 | 5 months ago | |
|
|
|
Cyclacel Pharmaceuticals,... | - | Translating cancer biology into medicines. | Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is a biopharmaceuti... | - |
United States
|
Dundee | United States (HQ) | 1996 | Biotechnology, Health Care +2 | [email protected] |
1
Low
|
12
|
2.5K (79%) | 1 year ago | Post Ipo Equity | 13 | 196.0M | 1293 | 7 months ago | |
|
|
|
Synta Pharmaceuticals | Not active anymore | Innovating patient care with advanced small molecule therapies for severe medica... | Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering... | - | - | - | - | 2000 | Biotechnology, Health Care +1 | [email protected] |
-1
N/A
|
195
|
518 | 10 years ago | Post Ipo Equity | 8 | 217.4M | 5344 | 2 L1Y FmG | |
|
|
|
FibroGen, Inc. | - | Committed to being a place where our people and science thrive. | We are committed to discovering, developing, and commercializing a pipeline of f... | - |
United States
|
San Francisco | United States (HQ) + 1 | 1993 | Biopharma, Biotechnology +2 | [email protected] |
1
Low
|
347
|
8.4K (40%) | 7 years ago | Post Ipo Equity | 7 | 308.0M | 16501 | 1 year ago | |
|
|
|
Inceptor Bio | - | Advancing Cell and Gene Therapies to Cure Cancer | Inceptor Bio is a clinical-stage biotech company pioneering next-generation cell... | - |
United States
|
Morrisville | United States (HQ) | 2020 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
28
|
657 (269%) | 2 years ago | Debt Financing | 5 | 87.6M | 4254 | 4 months ago | |
|
|
|
Sitka Biopharma | - | We're transforming chemotherapies to further benefit patients by enhancing effic... | Sitka Biopharma, a spin-off company of CDRD Ventures Inc., has developed a novel... | - |
Canada
|
- | Canada (HQ) + 1 | 2013 | Biopharma, Biotechnology +1 | - |
1
Low
|
909
|
577 | 6 years ago | Series Unknown | 5 | 5.5M | 347 | 1 6OV YXt | |
|
|
|
ADC Therapeutics | - | Innovating Science. Inspiring Hope. | ADC Therapeutics is a commercial-stage global pioneer in the field of antibody d... | - |
Switzerland
|
Lausanne | Switzerland (HQ) + 3 | 2011 | Biopharma, Biotechnology +1 | [email protected] |
1
Low
|
310
|
12.6K | 1 year ago | Post Ipo Equity | 11 | 856.6M | 19497 | 4 months ago | |
|
|
|
Xencor | - | Proteins by Design |
Proteins by Design Antibody and protein biotherapeutics are changing the way phy... |
- |
United States
|
Pasadena | United States (HQ) + 1 | 1997 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
271
|
4.2K (-13%) | 3 years ago | Post Ipo Equity | 11 | 482.6M | 9245 | 4 months ago | |
|
|
|
Chimeron Bio | - | Redefining genetic medicine with future-forward RNA technology designed to deliv... | Chimeron Bio is an early-stage biotech company focused on breakthrough treatment... | - |
United States
|
Philadelphia | United States (HQ) | 2015 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
12
|
345 | 4 years ago | Angel | 3 | 1.1M | 2317 | 6 months ago | |
|
|
|
OncoPrecision | - | Leveraging single-cell high-throughput biology and AI/ML to dramatically increas... | Leveraging single-cell high-throughput biology and AI/ML to dramatically increas... | - |
United States
|
New York | United States (HQ) + 1 | 2020 | Biotechnology, Health and Wellness | [email protected] |
1
Low
|
32
|
259 (339%) | 11 months ago | Convertible Note | 3 | 4.2M | 4133 | 4 months ago | |
|
|
|
Soricimed Biopharma Inc. | - | Dedicated to developing effective and novel targeted treatments for cancer. | Soricimed is a privately-held, clinical stage company dedicated to developing ef... | - |
Canada
|
- | Canada (HQ) + 1 | 2005 | Biopharma, Biotechnology +1 | [email protected] |
1
Low
|
12
|
286 (-58%) | 2 years ago | Grant | 5 | 3.3M | 601 | 1 year ago | |
|
|
|
GeneCast Biotechnology Co... | - | - | Founded in November, 2014, Genecast (Beijing) Biotechnology Co. is located in He... | - |
China
|
Beijing | China (HQ) | 2014 | Biotechnology, Health Care | [email protected] |
1
Low
|
21
|
931 (-100%) | 4 years ago | Series E | 5 | 93.5M | 328 | 4 jvA bRM | |
|
|
|
Mavupharma | - | Pioneering non-nucleotide modulators of the STING pathway for cancer and infecti... | Mavupharma is developing non-nucleotide, conditional modulators of the STING pat... | - | - | - | - | 2016 | Biotechnology, Health Care +2 | [email protected] |
1
Low
|
792
|
808 | 7 years ago | Series A | 1 | 20.0M | 68896 | 6 eq1 gV7 | |
|
|
|
VerImmune | - | Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer |
VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Thera... |
- |
United States
|
- | United States (HQ) + 1 | 2019 | Biotechnology, Health Care +1 | - |
1
Low
|
13
|
587 (-22%) | 1 year ago | Seed | 3 | 6.5M | 873 | 4 months ago | |
|
|
|
Sunesis Pharmaceuticals,... | Not active anymore | - | Sunesis is a biopharmaceutical company focused on the development and future com... | - |
United States
|
South San Francisco | United States (HQ) | 1987 | Biotechnology, Health Care +1 | [email protected] |
-1
N/A
|
42
|
1.2K (58%) | 8 years ago | Post Ipo Equity | 9 | 221.7M | 2415 | 7 IGX ZjE | |
|
|
|
辽宁依生生物制药有限公司 | - | Pioneering groundbreaking biotherapeutics for cancers and infectious diseases wi... | YS Biopharma is an international biopharmaceutical firm committed to discovering... | - | - | - | - | 2002 | Biopharma, Biotechnology +1 | [email protected] |
1
Low
|
26
|
241 | 1 year ago | Post Ipo Equity | 5 | 210.7M | 60572 | 10 a27 syW | |
|
|
|
EUSA Pharma | - | Part of Recordati Rare Diseases, the business unit dedicated to rare diseases in... | We are committed to transforming the lives of people affected by cancer or rare... | - |
United Kingdom
|
Hemel Hempstead | United Kingdom (HQ) | 2006 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
107
|
830 (-36%) | 15 years ago | Series Unknown | 7 | 54.2M | 13416 | 1 year ago | |
|
|
|
OncoTartis, Inc. | - | - | OncoTartis, Inc. is a private biotechnology company established in 2011. It is l... | - | - | - | - | 2009 | Biotechnology, Health Care | [email protected] |
1
Low
|
1
|
961 (-100%) | 7 years ago | Series Unknown | 1 | 6.0M | 141 | 9 Fsu 5mj | |
|
|
|
ARIZ Precision Medicine | - | Targeting Cancer at the Root Cause | ARIZ Precision Medicine is pre-clinical stage company aiming to selectively targ... | - |
United States
|
Davis | United States (HQ) | 2015 | Biotechnology, Health Care +1 | [email protected] |
1
Low
|
3
|
722 (3%) | 3 years ago | Convertible Note | 3 | 2.7M | 508 | 5 months ago |